DV
Dividend Vision

SPRB — Spruce Biosciences, Inc. Common Stock

Spruce Biosciences, Inc. Common Stock (SPRB)

Total return is -95.9% over the past 5.8 years, 238.0 points behind SPY at 142.1%. Its deepest 1-year drawdown was 77.3%.

Spruce Biosciences is a biopharmaceutical company developing novel therapies for rare neurological and endocrine disorders, including TA-ERT for Sanfilippo Syndrome Type B, Tildacerfont for a debilitating mood disorder, and SPR202 for Congenital Adrenal Hyperplasia. The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biotech development rather than income generation.

SPRB key facts

Asset type
Stock
Asset class
Equity
Inception date
10/09/2020
Last close
$52.64
Market cap
$122,476,368
Average volume
42300.0
Beta
3.208
Payout ratio
0.0
Forward P/E
0.0
EPS
$-36.10